Vanda Pharmaceuticals Inc. (VNDA) is a publicly traded Healthcare sector company. As of May 21, 2026, VNDA trades at $6.15 with a market cap of $365.62M and a P/E ratio of -1.52. VNDA moved +2.92% today. Year to date, VNDA is -21.47%; over the trailing twelve months it is +39.19%. Its 52-week range spans $3.81 to $9.94. Analyst consensus is strong buy with an average price target of $16.75. Rallies surfaces VNDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vanda Raises 2026 Revenue Outlook to $240–$290M After 26% Fanapt Growth: Fanapt net product sales rose 26% to $29.6 million in Q1 2026, driven by a 32% boost in total prescriptions and a 76% surge in new-to-brand prescriptions. The company launched NEREUS via its innovative direct-to-consumer platform, gained FDA approval for BYSANTI to treat bipolar I disorder and schizophrenia, and lifted 2026 revenue guidance to $240–$290 million.
| Metric | Value |
|---|---|
| Price | $6.15 |
| Market Cap | $365.62M |
| P/E Ratio | -1.52 |
| EPS | $-4.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.94 |
| 52-Week Low | $3.81 |
| Volume | 1.24K |
| Avg Volume | 0 |
| Revenue (TTM) | $217.78M |
| Net Income | $-239.55M |
| Gross Margin | 0.00% |
4 analysts cover VNDA: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.75.